๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II trial with carboplatinum (CBDCA, JM8) in refractory or relapsed ovarian cancer (OC)

โœ Scribed by J. Pohl; H. G. Meerpohl; A. Pfleiderer


Book ID
112785763
Publisher
Springer-Verlag
Year
1986
Tongue
English
Weight
126 KB
Volume
111
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Phase II trial of temsirolimus in patien
โœ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat